{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-189932","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2024-07-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.832460+00:00","generated_at":"2026-05-31T14:19:02.534083+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MiMedx Q2 revenue $87M (+7% YoY), GAAP EPS $0.12, Adjusted EBITDA margin 23%","bullets":["Net sales $87M, up 7% YoY; GAAP net income $18M, EPS $0.12.","Adjusted EBITDA $20M, margin 23% vs 17.4% in Q2 2023.","CEO reports competitive pressure from high-priced skin substitutes causing employee and customer attrition.","Launched HELIOGEN (first xenograft) and commenced RCT for EPIEFFECT.","Cash $69M; 2024 net sales growth guided to mid-to-high single digits."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-189932","json":"https://secwatch.observer/filing/0001193125-24-189932.json","markdown":"https://secwatch.observer/filing/0001193125-24-189932.md","text":"https://secwatch.observer/filing/0001193125-24-189932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524189932/0001193125-24-189932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000119312524189932/d866445d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T14:19:02.534083+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}